Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
Lilly Japan Suffers Negative Growth for 3rd Straight Year in 2022 as 2 Major LOEs Weigh
To read the full story
Related Article
- Innovative Brands to Drive Return to Growth at Lilly Japan after 2 Years of Decline: President
April 13, 2022
- Lilly Japan Set for Leading Spot in All Core Areas in 2025, “No Plan to Replicate” Redundancy Program: Chief
April 14, 2021
- Lilly Japan Chief Sees Continued Diabetes Investment as Key to Remaining in Top 10
June 22, 2020
- Lilly Expects Topline Data for 2 COVID-19 Drug Candidates by June-End, First Patient Dosed in Antibody Treatment Study: Japan Execs
June 3, 2020
BUSINESS
- Drug Makers Discontinue Sales of Alesion Dry Syrup, Generic Versions
October 3, 2023
- Meiji Launches Japan PIII of mRNA COVID Shot for BA.4/5 Strain
October 3, 2023
- Chugai Embraces ChatGPT to Streamline Internal Tasks, Search Research Papers and More
October 3, 2023
- Tarlige Tops July Rep Promotion Ranking, Takes Back Crown from Mounjaro for GPs: Intage
October 3, 2023
- Kyorin to Cut Non-Sales Jobs through Voluntary Buyout
October 3, 2023
“Time is the scarcest resource, and unless it is managed, nothing else can be managed.” - Peter DruckerSearching for the right candidate takes time… but how much time?The last thing you want is to waste time searching for the wrong…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…